참고문헌
- Yang L, Wang L, Zhang Y. Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol. 2016;5(1):1-20.
- Ansari J, Shackelford RE, El-Osta H. Epigenetics in nonsmall cell lung cancer: from basics to therapeutics. Transl Lung Cancer Res. 2016;5(2):155-71. https://doi.org/10.21037/tlcr.2016.02.02
- Li MJ, He Q, Li M, Luo F, Guan YS. Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. Onco Targets Ther. 2016;9:1291-302.
- Beom SH, Kim DW, Sim SH, Keam B, Park JH, Lee JO, et al. Gefitinib-induced interstitial lung disease in Korean lung cancer patients. Cancer Res Treat. 2016;48(1):88-97. https://doi.org/10.4143/crt.2014.201
- Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009;10(4):281-9. https://doi.org/10.3816/CLC.2009.n.039
- Whang CY. [Bibliographic study on the therapy of lung cancer by integrated oriental and western medicine]. J Korean Orient Med. 1995;16(2):177-94. Korean.
- Bang SH, Yoon JW, Cho CK, Shin JE, Lee YW, Yoo HS. A case series of survival outcomes in patients with advanced-stage IIIb/IV non-small-cell lung cancer treated with HangAm-plus. J Pharmacopuncture. 2012;15(2):31-5. https://doi.org/10.3831/KPI.2012.15.2.031
- Yim MH, Shin JW, Son JY, Oh SM, Han SH, Cho CK, et al. Soluble components of Hericium erinaceum induce NK cell activation via production of interleukin-12 in mice splenocytes. Acta Pharmacol Sin. 2007;28(6):901-7. https://doi.org/10.1111/j.1745-7254.2007.00577.x
- Bi X, Xia X, Mou T, Jiang B, Fan D, Wang P, et al. Anti-tumor activity of three ginsenoside derivatives in lung cancer is associated with Wnt/beta-catenin signaling inhibition. Eur J Pharmacol. 2014;742:145-52. https://doi.org/10.1016/j.ejphar.2014.08.032
- Cheon SH, Kim KS, Kim S, Jung HS, Choi WC, Eo WK. Efficacy and safety of Rhus verniciflua stokes extracts in patients with previously treated advanced non-small cell lung cancer. Forsch Komplementmed. 2011;18(2):77-83.
- Park SJ, Kang HJ, Park JH, Cho CK, Yoo HS. [A case report of a clinically diagnosed advanced lung cancer patient after treatment with gunchilgyebok-jung]. J Korean Tradit Oncol. 2015;20(1):23-9. Korean.
- Mok TS, Wu YL, Yang CH, Chu DT, Saijo N, Sunpaweravong P, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57. https://doi.org/10.1056/NEJMoa0810699
- Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, et al. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial. Trials. 2015;16:146. https://doi.org/10.1186/s13063-015-0685-2
- Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ. Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study. Complement Ther Med. 2014;22(6):1010-8. https://doi.org/10.1016/j.ctim.2014.10.001
피인용 문헌
- Integrative Medicine for Postoperative Patients: A Survey of Korean Medicine Doctors vol.2017, 2017, https://doi.org/10.1155/2017/4650343